ENTA

Enanta Pharmaceuticals Inc

ENTA, USA

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. It has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.

https://www.enanta.com

Stock Price

$ 0.00

0% increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
ENTA
stock
ENTA

Aug Macro: Is Gentex Corporation GTX stock worth holding before Fed meeting - Weekly Earnings Recap & Safe Entry Momentum Stock Tips moha.gov.vn

Read more →
ENTA
stock
ENTA

Have Insiders Sold Enanta Pharmaceuticals Shares Recently? simplywall.st

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$19.125

Analyst Picks

Strong Buy

2

Buy

1

Hold

2

Sell

1

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very High

4.77

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-28.90 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-6.66 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-52.54 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very Low

3.34

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 87.78% of the total shares of Enanta Pharmaceuticals Inc

1.

Farallon Capital Management, L.L.C.

(9.9274%)

since

2025/06/30

2.

Krensavage Asset Management, LLC

(9.8908%)

since

2025/06/30

3.

Vanguard Group Inc

(9.2463%)

since

2025/06/30

4.

BlackRock Inc

(8.6393%)

since

2025/06/30

5.

Millennium Management LLC

(6.8229%)

since

2025/06/30

6.

Marshall Wace Asset Management Ltd

(4.0107%)

since

2025/06/30

7.

Vanguard Total Stock Mkt Idx Inv

(2.8815%)

since

2025/07/31

8.

Stonepine Capital Management Llc

(2.8257%)

since

2025/06/30

9.

HHG PLC

(2.4499%)

since

2025/06/30

10.

Geode Capital Management, LLC

(2.2724%)

since

2025/06/30

11.

iShares Russell 2000 ETF

(2.2242%)

since

2025/08/31

12.

State Street Corp

(2.1998%)

since

2025/06/30

13.

Renaissance Technologies Corp

(2.1962%)

since

2025/06/30

14.

AQR Capital Management LLC

(1.8529%)

since

2025/06/30

15.

Vanguard Strategic Small-Cap Equity Inv

(1.5815%)

since

2025/06/30

16.

Morgan Stanley - Brokerage Accounts

(1.3403%)

since

2025/06/30

17.

D. E. Shaw & Co LP

(1.3204%)

since

2025/06/30

18.

Dimensional Fund Advisors, Inc.

(1.2987%)

since

2025/06/30

19.

Trexquant Investment LP

(1.2394%)

since

2025/06/30

20.

Northern Trust Corp

(1.1751%)

since

2025/06/30

21.

Vanguard Institutional Extnd Mkt Idx Tr

(0.9783%)

since

2025/07/31

22.

Vanguard VIF Small Co Gr

(0.9639%)

since

2025/06/30

23.

Fidelity Small Cap Index

(0.9423%)

since

2025/06/30

24.

Jacobs Levy Equity Management, Inc.

(0.8985%)

since

2025/06/30

25.

iShares Russell 2000 Value ETF

(0.858%)

since

2025/08/31

26.

Vanguard Strategic Equity Inv

(0.8455%)

since

2025/06/30

27.

Sio Capital Management, LLC

(0.8363%)

since

2025/06/30

28.

Charles Schwab Investment Management Inc

(0.7702%)

since

2025/06/30

29.

UBS (Lux) EF Biotech (USD) P-acc

(0.7461%)

since

2025/05/31

30.

Vanguard Explorer Inv

(0.5575%)

since

2025/06/30

31.

iShares Biotechnology ETF

(0.5573%)

since

2025/08/31

32.

BlackRock Advantage Small Cap Core Instl

(0.5124%)

since

2025/07/31

33.

Fidelity Extended Market Index

(0.5059%)

since

2025/07/31

34.

Vanguard Russell 2000 ETF

(0.4476%)

since

2025/07/31

35.

Schwab US Small-Cap ETFâ„¢

(0.429%)

since

2025/08/30

36.

JPMorgan Small Cap Value I

(0.3486%)

since

2025/07/31

37.

Acadian Global Small-Cap Equity CIT Cl A

(0.3379%)

since

2025/03/04

38.

State St Russell Sm Cap® Indx SL Cl I

(0.3377%)

since

2025/08/31

39.

Dimensional US Small Cap ETF

(0.2667%)

since

2025/08/29

40.

Schwab Small Cap Index

(0.2491%)

since

2025/07/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

-0.87

EPS Estimate

-1.01

EPS Difference

0.14

Surprise Percent

13.8614%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Weak Deep Value(2)
Defensive
Moderately Defensive(5.5)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(3.8)
GARP
Not Attractive for GARP(1)
Growth
Weak Growth Prospect(1)
Momentum
No Momentum(3)
Net Net
Not Undervalued (Net-Net)(2)
Quality
Low Quality Business(1.5)
Value
Overpriced(2)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.